reports
EQS-News: Mainz Biomed präsentiert Ergebnisse der Darmkrebsfrüherkennu...
Emittent / Herausgeber: Mainz BioMed N.V. / Schlagwort(e): Konferenz Mainz Biomed präsentiert Ergebnisse der Darmkrebsfrüherkennungsstudie eAArly DETECT auf der Digestive Disease Week 2024 07.05.2024 / 14:01 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Mainz Biomed präsentiert Ergebnisse der Darmkrebsfrüherkennungsstudie eAArly DETECT auf der Digestive Disease Week 2024 Die Studiendaten von eAArly DETECT belegten eine Sensitivität für Darmkrebs von 97% mit einer Spezifität von 97% und eine Sensitivität für fortgeschrittene Adenom...
EQS-News: Mainz Biomed to Present Results of Colorectal Cancer Screeni...
Issuer: Mainz BioMed N.V. / Key word(s): Conference Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C. 07.05.2024 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C. The eAArly DETECT results reported a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82% BERKELE...
EQS-News: Mynaric selected by Rocket Lab for Space Development Agency’...
EQS-News: Mynaric AG / Key word(s): Incoming Orders Mynaric selected by Rocket Lab for Space Development Agency’s Tranche 2 Transport Layer – Beta Program 07.05.2024 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Laser Communications Manufacturer Expands Customer Roster LOS ANGELES, May 7, 2024 – (NASDAQ: MYNA) (FRA: M0YN), a leading provider of industrialized, cost-effective and scalable laser communications products, today announced that it has been selected by Rocket Lab USA, Inc (NASDAQ: RKLB) to supply free space optical ...
EQS-News: Mynaric wurde von Rocket Lab für das Tranche 2 Transport Lay...
EQS-News: Mynaric AG / Schlagwort(e): Auftragseingänge Mynaric wurde von Rocket Lab für das Tranche 2 Transport Layer - Beta Programm der Space Development Agency ausgewählt 07.05.2024 / 14:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Hersteller für Laserkommunikation erweitert Kundenstamm LOS ANGELES, 7. Mai 2024 – Mynaric (NASDAQ: MYNA) (FRA: M0YN), ein führender Großserienanbieter von kosteneffektiven und in skalierbaren Mengen produzierten Laserkommunikationsprodukten, gab heute bekannt, dass es von Rocket Lab USA, Inc. (...
Hitachi Energy supports long-term operation of largest HVDC-connected ...
Hitachi Energy supports long-term operation of largest HVDC-connected wind energy project in U.S. Multi-year agreement provides service solutions to the SunZia Transmission Project, linking New Mexico’s wind farms to Arizona’s grid, increasing renewable energy to Western States Zurich, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- Hitachi Energy announced that it has signed a multi-year agreement with Pattern Energy to support its high-voltage direct current (HVDC) technologies for the SunZia Transmission Project. The link will connect the 3,515-megawatt (MW) SunZia Wind project in New ...
Interim report for Q2 and H1 2023/24 (the period 01.10.2023 - 31.03.20...
Interim report for Q2 and H1 2023/24 (the period 01.10.2023 - 31.03.2024) Nørresundby, Denmark, 7 May 2024Announcement no. 25/2024 Q2 MEETS EXPECTATIONS, WITH GROWING ORDERS AND SALES, IN A MARKET, WHERE CUSTOMER INVENTORIES ARE NORMALIZING AND REORDERING IS BEGINNING TO PICK UP. “The results for Q2 are in line with our expectations for the quarter, reaching sales of DKK 125 million and trimming inventory by DKK 8 million during the quarter. In Q2, we furthermore see an increase in our order intake, indicating a shift towards more typical market dynamics, characterized by shorter ...
Bridger Aerospace Announces Schedule for its First Quarter 2024 Earnin...
Bridger Aerospace Announces Schedule for its First Quarter 2024 Earnings Release and Conference Call BELGRADE, Mont., May 07, 2024 (GLOBE NEWSWIRE) -- Bridger Aerospace Group Holdings, Inc. (“Bridger” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation’s largest aerial firefighting companies, today announced that it will release financial results for the first quarter ended March 31, 2024 on Monday, May 13, 2024 after the market close. Management will conduct an investor conference call on Monday, May 13, 2024, at 5:00 p.m. Eastern Time (3:00 p.m. Mountain Time) to discus...
Form 8.3 - UK Commercial Property REIT Limited
Form 8.3 - UK Commercial Property REIT Limited 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securitie...
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® ...
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting IBSRELA® (tenapanor) will be presented at the 2024 Digestive Disease Week Conference (DDW), to be held May 18-2...
Mainz Biomed to Present Results of Colorectal Cancer Screening Study e...
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C. The eAArly DETECT results reported a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82% BERKELEY, Calif. and MAINZ, Germany, May 07, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, will present an analysis from its eAArly DETECT study at Digestive Disease Week (DDW) 2024 in Washington D.C. from May ...
Zscaler Joins Forces with Google to Offer Unparalleled Zero Trust Data...
Zscaler Joins Forces with Google to Offer Unparalleled Zero Trust Data and Threat Protection Enterprises can now Ensure Secure, Remote Access to Private Web Apps across devices and locations with Zscaler and Google Chrome Enterprise SAN JOSE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ZS), the leader in cloud security, has collaborated with Google on a joint zero trust architecture with Chrome Enterprise. This powerful combination brings the power of Zscaler Private Access™ (ZPA) enabling zero trust secure access to private applications to anyone across different locations and d...
Great Lakes Reports First Quarter 2024 Results
Great Lakes Reports First Quarter 2024 Results First quarter net income of $21.0 millionFirst quarter adjusted EBITDA of $42.9 millionDredging backlog of $879.4 million at March 31, 2024 HOUSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Great Lakes Dredge & Dock Corporation (“Great Lakes” or the “Company”) (Nasdaq: GLDD), the largest provider of dredging services in the United States, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights Revenue was $198.7 millionTotal operating profit was $31.5 millionNet income was $21.0 millionAdjusted ...
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and...
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, a program granted Fast Track Designation by the US FDAData presented at the 2024 AACR demonstrate NXP900's robust activity in non-small cell cancer cell linesSeveral clinical data updates expected in 2H 2024 FORT LEE, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focus...
Alphawave IP Group: 1 director
A director at Alphawave IP Group maiden bought 100,000 shares at 117p and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleo...
Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting BEDMINSTER, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that , will be presenting two abstracts at the being held May 7-11, 2024 in Baltimore highlighting data from ex vivo, in vitro and in vivo studies evaluating the use of Matinas’ LNC platform for the uptake ...
Sales and Profitability Growth Drive Continuing Momentum in L.B. Foste...
Sales and Profitability Growth Drive Continuing Momentum in L.B. Foster First Quarter 2024 Results; Company Reaffirms 2024 Guidance First quarter net sales of $124.3 million up 7.6% year over year (up 16.9% organically1); gross profit of $26.2 million up 12.7% year over year with gross margins expanding 90 basis points ("bps") to 21.1%.First quarter net income of $4.4 million favorable $6.6 million year over year; first quarter adjusted EBITDA1 of $5.9 million up 32.4% year over year.Net debt1 of $74.9 million down $2.5 million and Gross Leverage Ratio1 of 2.2x down 0.2x versus last year's ...
Core Molding Technologies Reports Fiscal 2024 First Quarter Results
Core Molding Technologies Reports Fiscal 2024 First Quarter Results COLUMBUS, Ohio, May 07, 2024 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico today reports financial and operating results for the three months ended March 31, 2024. First Quarter 2024 Highlights Total net sales of ...
Whitestone REIT Board Leaders Issue Open Letter to Shareholders
Whitestone REIT Board Leaders Issue Open Letter to Shareholders HOUSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Whitestone REIT (NYSE: WSR) (“Whitestone” or the “Company”) today issued a shareholder letter from independent Board Chair David Taylor and Chair of the Nominating and Corporate Governance Committee, Nandita Berry. In their joint letter, Ms. Berry and Mr. Taylor detail the challenging and decisive actions they took as change agents to terminate the former CEO James Mastandrea for cause, revitalize corporate governance, and oversee the successful ongoing value creation plan under the ...
BioAtla to Announce First Quarter 2024 Financial Results and Provide B...
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024 SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 14, 2024 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2024 and provide business highlights. Conference Call and Webcas...
4DMT to Participate in Upcoming Investor Conference
4DMT to Participate in Upcoming Investor Conference EMERYVILLE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in a fireside chat at an upcoming investor conference in May. Members of the management team will also be available for one-on-one meetings. Bank of America Health Care Conference 2024 Presentation Date:Tuesday, May 14, 2...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.